Department of Oncology, Jianhu People's Hospital, Yancheng, Jiangsu, China.
Eur Rev Med Pharmacol Sci. 2018 May;22(10):3038-3046. doi: 10.26355/eurrev_201805_15061.
Recent studies reveal that hepatocellular carcinoma (HCC) express aberrant microRNAs. Dysregulation of miR-877-5p has been observed in HCC. The objective of the present study was to explore the clinical significance, function and underlying mechanism of miR-877-5p in HCC.
Quantitative reverse transcription PCR (qRT-PCR) was used to measure the levels of miR-877-5p in HCC specimens and HCC cell lines. Correlations between miR-877-5p expression and the clinicopathological features and prognosis of HCC patients were then evaluated. MTT assays, colony formation assays, scratch test, transwell assays were used to explore the biological function of miR-877-5p in HCC. A luciferase reporter assay and Western blot were conducted to confirm the target gene of miR-877-5p, and the results were validated in HCC cell lines.
We found that the expression of miR-877-5p was downregulated in HCC tissues or cell lines. Clinicopathologic analysis revealed that low miR-877-5p expression correlated with histologic grade (p = 0.008) and TNM stage (p = 0.018). The Kaplan-Meier method indicated that low miR-877-5p levels in HCC were associated with shorter overall survival (p = 0.0041) and disease-free survival (p = 0.0005). Multivariate analysis demonstrated that miR-877-5p expression was an independent poor prognostic factor for HCC patients. Functional assay revealed that upregulation of miR-877-5p could inhibit proliferation, migration, and invasion of HCC cells in vitro. We further identified cyclin-dependent kinase 14 (CDK14) as a direct target of miR-877-5p in HCC cells. Ectopic expression of CDK14 reversed the inhibitory effects of miR-877-5p.
Low miR-877-5p expression was a poor prognostic factor for HCC patients, and miR-877-5p functioned as a tumor suppressor in HCC cells via targeting CDK14.
最近的研究表明肝癌(HCC)表达异常的 microRNAs。miR-877-5p 的失调已在 HCC 中观察到。本研究的目的是探讨 miR-877-5p 在 HCC 中的临床意义、功能和潜在机制。
采用定量逆转录 PCR(qRT-PCR)测量 HCC 标本和 HCC 细胞系中 miR-877-5p 的水平。然后评估 miR-877-5p 表达与 HCC 患者临床病理特征和预后的相关性。MTT 测定、集落形成测定、划痕试验、Transwell 测定用于探讨 miR-877-5p 在 HCC 中的生物学功能。通过荧光素酶报告基因测定和 Western blot 验证 miR-877-5p 的靶基因,并在 HCC 细胞系中进行验证。
我们发现 miR-877-5p 在 HCC 组织或细胞系中表达下调。临床病理分析显示,低 miR-877-5p 表达与组织学分级(p=0.008)和 TNM 分期(p=0.018)相关。Kaplan-Meier 法表明 HCC 中低 miR-877-5p 水平与总生存期(p=0.0041)和无病生存期(p=0.0005)较短相关。多变量分析表明,miR-877-5p 表达是 HCC 患者的独立不良预后因素。功能测定表明,miR-877-5p 的上调可抑制 HCC 细胞在体外的增殖、迁移和侵袭。我们进一步鉴定出细胞周期蛋白依赖性激酶 14(CDK14)是 HCC 细胞中 miR-877-5p 的直接靶标。CDK14 的异位表达逆转了 miR-877-5p 的抑制作用。
低 miR-877-5p 表达是 HCC 患者的不良预后因素,miR-877-5p 通过靶向 CDK14 在 HCC 细胞中发挥肿瘤抑制作用。